AbbVie (ABBV) Total Liabilities (2012 - 2026)
AbbVie (ABBV) reported Total Liabilities of $143.1 billion for Q1 2026, up 6.22% year-over-year from $134.7 billion in Q1 2025, and up 4.29% on a QoQ basis from $137.2 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Total Liabilities data on file, last reported at $143.1 billion in Q1 2026.
- Quarterly Total Liabilities rose 6.22% year-over-year to $143.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.1 billion (up 6.22% YoY) and the FY2025 annual result came in at $137.2 billion, up 4.09% from the prior year.
- Total Liabilities rose to $143.1 billion in Q1 2026 per ABBV's latest filing, from $137.2 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $143.1 billion in Q1 2026 and bottomed at $121.2 billion in Q1 2023.
- The 5-year median for Total Liabilities is $131.8 billion (2024), against an average of $131.1 billion.
- The widest annual swing landed in 2022, when Total Liabilities fell 7.38%; it then grew 16.15% in 2024.
- Tracing ABBV's Total Liabilities over 5 years: stood at $121.5 billion in 2022, then rose by 2.3% to $124.3 billion in 2023, then rose by 6.02% to $131.8 billion in 2024, then grew by 4.09% to $137.2 billion in 2025, then grew by 4.29% to $143.1 billion in 2026.
- Per Business Quant, the three latest ABBV Total Liabilities figures stand at $143.1 billion (Q1 2026), $137.2 billion (Q4 2025), and $136.5 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 85.38 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.71 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 143.08 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 82.75 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 66.37 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 60.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.08 Bn |
| Dec 31, 2025 | 137.19 Bn |
| Sep 30, 2025 | 136.54 Bn |
| Jun 30, 2025 | 137.32 Bn |
| Mar 31, 2025 | 134.70 Bn |
| Dec 31, 2024 | 131.80 Bn |
| Sep 30, 2024 | 137.35 Bn |
| Jun 30, 2024 | 135.12 Bn |
| Mar 31, 2024 | 140.83 Bn |
| Dec 31, 2023 | 124.31 Bn |
| Sep 30, 2023 | 124.09 Bn |
| Jun 30, 2023 | 122.47 Bn |
| Mar 31, 2023 | 121.24 Bn |
| Dec 31, 2022 | 121.52 Bn |
| Sep 30, 2022 | 125.30 Bn |
| Jun 30, 2022 | 128.50 Bn |
| Mar 31, 2022 | 126.90 Bn |
| Dec 31, 2021 | 131.09 Bn |
| Sep 30, 2021 | 135.28 Bn |
| Jun 30, 2021 | 135.38 Bn |
| Mar 31, 2021 | 136.77 Bn |
| Dec 31, 2020 | 137.47 Bn |
| Sep 30, 2020 | 134.33 Bn |
| Jun 30, 2020 | 134.80 Bn |
| Mar 31, 2020 | 98.61 Bn |
| Dec 31, 2019 | 97.29 Bn |
| Sep 30, 2019 | 67.67 Bn |
| Jun 30, 2019 | 65.71 Bn |
| Mar 31, 2019 | 64.60 Bn |
| Dec 31, 2018 | 67.80 Bn |
| Sep 30, 2018 | 69.09 Bn |
| Jun 30, 2018 | 65.02 Bn |
| Mar 31, 2018 | 65.79 Bn |
| Dec 31, 2017 | 65.69 Bn |
| Sep 30, 2017 | 70.33 Bn |
| Jun 30, 2017 | 67.01 Bn |
| Mar 31, 2017 | 65.59 Bn |
| Dec 31, 2016 | 61.46 Bn |
| Sep 30, 2016 | 68.97 Bn |
| Jun 30, 2016 | 68.35 Bn |
| Mar 31, 2016 | 55.08 Bn |
| Dec 31, 2015 | 49.11 Bn |
| Sep 30, 2015 | 54.75 Bn |
| Jun 30, 2015 | 55.40 Bn |
| Mar 31, 2015 | 27.85 Bn |
| Dec 31, 2014 | 25.77 Bn |
| Sep 30, 2014 | 28.45 Bn |
| Jun 30, 2014 | 23.83 Bn |
| Mar 31, 2014 | 23.96 Bn |
| Dec 31, 2013 | 24.71 Bn |
| Sep 30, 2013 | 24.68 Bn |
| Jun 30, 2013 | 24.35 Bn |
| Mar 31, 2013 | 24.21 Bn |
| Dec 31, 2012 | 26.83 Bn |